0000000000341976

AUTHOR

Vladimir Tesar

showing 2 related works from this author

Incidence of Kidney Replacement Therapy and Subsequent Outcomes Among Patients With Systemic Lupus Erythematosus: Findings From the ERA Registry.

2022

RATIONALE AND OBJECTIVE: There is a dearth of data characterizing patients requiring kidney replacement therapy (KRT) for kidney failure due to systemic lupus erythematosus (SLE) and their clinical outcomes. The aim of this study was to describe trends in incidence and prevalence of KRT among these patients as well as to compare their outcomes to patients treated with KRT for diseases other than SLE.STUDY DESIGN: Retrospective cohort study based on kidney registry data.SETTING & PARTICIPANTS: Patients recorded in 14 registries of patients receiving kidney replacement therapy that provided data to the European Renal Association (ERA) Registry between 1992 and 2016.PREDICTOR: SLE as cause…

Malekidney diseasemedicine.medical_treatmentMAINTENANCE DIALYSIS030232 urology & nephrologyLupus nephritislupus nephritis (LN)0302 clinical medicineLupus Erythematosus Systemickidney replacement therapy (KRT)RegistriesRenal InsufficiencyKidney transplantationRISKeducation.field_of_studyKidneyregistry studyIncidence (epidemiology)IncidenceSTAGE RENAL-DISEASELupus Nephritis3. Good healthEuropeRenal Replacement Therapymedicine.anatomical_structureNephrologySURVIVALFemalemedicine.medical_specialtyprevalencePopulationkidney transplantationUNITED-STATESsurvival03 medical and health sciencesAFRICAN-AMERICAN PATIENTSInternal medicinemedicineHumansESRDeducationNEPHRITISDialysisRetrospective Studies030203 arthritis & rheumatologyProportional hazards modelbusiness.industryTRANSPLANTATIONMORTALITYRetrospective cohort studymedicine.diseasekidney failureend-stage renal disease (ESRD)3121 General medicine internal medicine and other clinical medicineSystemic lupus erythematosus (SLE)Kidney Failure ChronicprognosisbusinessAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
researchProduct

The switch from proteasome to immunoproteasome is increased in circulating cells of patients with fast progressive immunoglobulin A nephropathy and a…

2021

  The proteasome to immunoproteasome (iPS) switch consists of β1, β2 and β5 subunit replacement by low molecular weight protein 2 (LMP2), LMP7 and multicatalytic endopeptidase-like complex-1 (MECL1) subunits, resulting in a more efficient peptide preparation for major histocompatibility complex 1 (MHC-I) presentation. It is activated by toll-like receptor (TLR) agonists and interferons and may also be influenced by genetic variation. In a previous study we found an iPS upregulation in peripheral cells of patients with immunoglobulin A nephropathy (IgAN). We aimed to investigate in 157 IgAN patients enrolled through the multinational Validation Study of the Oxford Classification of IgAN (VAL…

0301 basic medicinemedicine.medical_specialtyProteasome Endopeptidase Complex030232 urology & nephrologyCD46; IgA nephropathy; biomarkers; complement; immune proteasome; progression; risk factorsMajor histocompatibility complexMembrane Cofactor Protein03 medical and health sciences0302 clinical medicineDownregulation and upregulationInternal medicinemedicinerisk factorsHumanscomplementRNA MessengerReceptorCD46Transplantationmedicine.diagnostic_testbiologybusiness.industrybiomarkersPSMB8Glomerulonephritis IGAIgA nephropathyPSMB9medicine.diseaseUp-RegulationTLR2030104 developmental biologyEndocrinologyNephrologybiology.proteinprogressionRenal biopsyimmune proteasomebusinessKidney diseaseGenome-Wide Association StudyNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct